Design, synthesis, docking study, &#945;-glucosidase inhibition, and cytotoxic activities of acridine linked to thioacetamides as novel agents in treatment of type 2 diabetes.

Mohammadi-Khanaposhtani, Maryam; Rezaei, Sepideh; Khalifeh, Reza; Imanparast, Somaye; Faramarzi, Mohammad Ali; Bahadorikhalili, Saeed; Safavi, Malihe; Bandarian, Fatemeh; Nasli Esfahani, Ensieh; Mahdavi, Mohammad; Larijani, Bagher

Design, synthesis, docking study, α-glucosidase inhibition, and cytotoxic activities of acridine linked to thioacetamides as novel agents in treatment of type 2 diabetes.

Mohammadi-Khanaposhtani, Maryam; Rezaei, Sepideh; Khalifeh, Reza; Imanparast, Somaye; Faramarzi, Mohammad Ali; Bahadorikhalili, Saeed; Safavi, Malihe; Bandarian, Fatemeh; Nasli Esfahani, Ensieh; Mahdavi, Mohammad; Larijani, Bagher.

Afiliación

Mohammadi-Khanaposhtani M; Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Rezaei S; Department of Chemistry, Shiraz University of Technology, Shiraz, Iran.
Khalifeh R; Department of Chemistry, Shiraz University of Technology, Shiraz, Iran.
Imanparast S; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Iran.
Faramarzi MA; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Iran.
Bahadorikhalili S; School of Chemistry, College of Science, University of Tehran, Tehran, Iran.
Safavi M; Department of Biotechnology, Iranian Research Organization for Science and Technology (IROST), Tehran, Iran.
Bandarian F; Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Nasli Esfahani E; Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mahdavi M; Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Larijani B; Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: emrc@tums.ac.ir.

Bioorg Chem ; 80: 288-295, 2018 10.

Article en En | MEDLINE | ID: mdl-29980114

Asunto(s)

Diabetes Mellitus Tipo 2/tratamiento farmacológico; Diseño de Fármacos; Inhibidores de Glicósido Hidrolasas/síntesis química; Tioacetamida/química; alfa-Glucosidasas/metabolismo; Acridinas/química; Sitios de Unión; Dominio Catalítico; Línea Celular; Supervivencia Celular/efectos de los fármacos; Diabetes Mellitus Tipo 2/metabolismo; Inhibidores de Glicósido Hidrolasas/farmacología; Inhibidores de Glicósido Hidrolasas/uso terapéutico; Humanos; Hipoglucemiantes/síntesis química; Hipoglucemiantes/farmacología; Hipoglucemiantes/uso terapéutico; Cinética; Simulación del Acoplamiento Molecular; Relación Estructura-Actividad; Tioacetamida/farmacología; Tioacetamida/uso terapéutico; alfa-Glucosidasas/química

Palabras clave

Acridine; Docking study; Thioacetamide; Type 2 diabetes; α-Glucosidase

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tioacetamida / Diseño de Fármacos / Diabetes Mellitus Tipo 2 / Alfa-Glucosidasas / Inhibidores de Glicósido Hidrolasas Límite: Humans Idioma: En Revista: Bioorg Chem Año: 2018 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google